Agfa submitted mdr report #1225058-2010-00001 to the fda on 06/07/2010 for a site in the us.A (b)(6) occurrence is being reported for the same issue/same device: impac cv results management administration tool (rmat).This in an internal discovery determined during the implementation of the associated problem correction plan, rmat verification, as reported in fda z-2112-10.
|
An agfa clinical analyst performed a retro-analysis and reported the findings to agfa service and agfa product quality manager.Agfa's investigation into this occurrence of rmat customizations has revealed that this specific change had the potential to introduce clinical inaccuracies in pt reports.Specifically: the mitral valve leaflets appear normal" has been changed to:"there is partial rupture of the anterolateral papillary muscle".In this issue, the original sentence states the mitral valve leaflets are normal.The sentence change however, contains clinically different content indicating the presence of anterolateral papillary muscle rupture.This could lead to incorrect diagnosis and or inappropriate treatment as a papillary muscle rupture would indicate the presence of mitral regurgitation and may indicate the need for mitral valve leaflet repair.If this sentence change is found in the production environment, the ca believes that the potential for misdiagnosis is greater than the potential for inappropriate treatment as the referring surgeon would assess the images prior to intervention.Potential impact: if the change was made after reports had been generated with the original sentence selected, those reports prior to the change could display incorrect clinical data if viewed in rm or if used as a template for a repeat study on that pt.As soon as agfa is made aware of any affected reports related to this specific finding, follow up med's will be submitted for each associated study date and respective medical records number/s (mrn) identified.There has been no reported pt harm for this occurrence.A reportable correction is underway for this issue and has been reported to the fda via ref # z-2112-10.Agfa will follow the rmat post market verification work instruction to correct the sentence finding.Any further investigation for the site described in this report will be documented in the ongoing cfr part 806 reporting.
|